New Progress Of TKI Combined With Double Immunotherapy For Renal Cancer
ADC评论
July 16, 2022
Exelixis Announces Cabozantinib in Combination with Nivolumab and Ipilimumab Significantly Improved Progression-Free Survival in Phase 3 COSMIC-313 Pivotal Trial in Patients with Previously Untreated Advanced
